Primer pair, gene probe, kit and application of primer pair, gene probe and kit in identifying acinetobacter baumannii
By combining RPA isothermal amplification technology with test strip detection, and designing specific primers and gene probes, the problems of long time consumption and high cost of existing Acinetobacter baumannii detection methods have been solved, achieving rapid, sensitive, simple and accurate identification results.
Patent Information
- Application Number
- CN202411294355.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-22
AI Technical Summary
Existing methods for detecting Acinetobacter baumannii are cumbersome, time-consuming, and costly, and are difficult to perform quickly, sensitively, and accurately at the grassroots level or on-site, with long culture times and the risk of contamination.
Using RPA isothermal amplification technology combined with test strip detection, specific primers and gene probes were designed. The colorimetric reaction of colloidal gold test strips was used to rapidly identify Acinetobacter baumannii. The RPA-amplified sample was then dropped onto the test strip for visual detection.
It enables rapid, sensitive, highly specific, easy-to-operate, and low-cost identification of Acinetobacter baumannii, making it suitable for use at the grassroots level or in the field. It reduces testing time and cost and improves identification accuracy.
Smart Images

Figure CN118995976A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of rapid in vitro detection, and specifically relates to a primer pair, a gene probe and a kit and applications thereof in identifying Acinetobacter baumannii. Background Art
[0002] Acinetobacter baumannii is a non-fermenting aerobic Gram-negative coccobacillus belonging to the Moraxellaceae family. It is an opportunistic pathogen that can cause nosocomial infections, mainly bacteremia, urinary tract infections, secondary meningitis, or other infections caused by the use of catheters and ventilators. Many studies have shown that Acinetobacter baumannii is an important conditional pathogen causing nosocomial infections and a common pathogen causing pneumonia and sepsis. In addition, the detection rate of multidrug-resistant and pan-drug-resistant Acinetobacter baumannii is increasing, so that there are fewer and fewer antibiotics available clinically, and many patients even have no drugs available. Acinetobacter baumannii infection is common in critically ill patients, often accompanied by infections with other bacteria and (or) fungi. The mortality rate of patients infected with Acinetobacter baumannii is high. At present, it has developed into multidrug-resistant Acinetobacter baumannii (MDRAB), extensively drug-resistant Acinetobacter baumannii (XDRAB), and pan-drug-resistant Acinetobacter baumannii (PDRAB). At present, the detection of bacteria in clinical practice is mainly carried out through paper culture method, imaging detection, NGS, drug sensitivity detection, or PCR method to detect pathogen genes. Although the PCR method is short in time, it is relatively cumbersome and has too high requirements for the laboratory, which is not suitable for clinical promotion. These conventional detection methods have long operation time, too high requirements for the laboratory, and rely on expensive experimental equipment. In addition, the strain separation and processing operations are complicated and there is a certain risk of infection, which is not convenient for detection at the grassroots level or on-site. Therefore, it is necessary to develop an efficient, accurate, sensitive, easy-to-operate, and readily monitorable Acinetobacter baumannii detection and analysis method, which is of great significance for the scientific research and application of Acinetobacter baumannii.
[0003] RPA isothermal amplification technology, also known as recombinase polymerase amplification technology (RPA), is a new nucleic acid isothermal amplification technology developed by Piepenburg et al. in 2006 using protein recombination and repair involved in cell DNA synthesis. It is known as a nucleic acid detection technology that can replace PCR. RPA technology mainly relies on three enzymes: recombinase that can bind to single-stranded nucleic acids (oligonucleotide primers), single-stranded DNA binding protein (SSB) and strand displacement DNA polymerase. The reaction process of RPA is first that the recombinase binds to the primer to form a protein-DNA complex, and then the protein-DNA complex searches for homologous sequences in double-stranded DNA. Once the primer finds the target homologous sequence, a chain exchange reaction will occur to form and initiate DNA synthesis, and the exponential amplification of the target sequence on the template will be completed within a few minutes. The replaced DNA chain binds to SSB (single-stranded DNA binding protein) to keep the DNA in a single-stranded state and prevent it from being hydrolyzed by nucleases. The mixture of these three enzymes is also active at room temperature, with the optimal reaction temperature at around 39°C. With only a small amount of sample preparation, it can amplify as few as 1-10 DNA copies within 10 minutes. It has the advantages of high sensitivity, selectivity, portability, rapidity, and the ability to perform multiple amplifications.
[0004] The main principle of colloidal gold test strips is to use cellulose acetate membrane as a carrier, utilize the capillary action of the microporous membrane, and slowly transfer the liquid dripped on one end of the membrane strip to the other end, and use the colloidal gold to show the color reaction through the antigen-antibody binding of the streaked line. The biggest feature of this method is that it is simple to operate, fast and rapid, sensitive and accurate, safe and simple, low cost, and does not require professional personnel and instruments and equipment. The negative and positive color development is obvious, and the test results can usually be observed by the naked eye within 3-5 minutes.
[0005] Currently, the traditional methods for identifying Acinetobacter baumannii include: imaging, histopathology, direct culture, serological methods, drug sensitivity testing, molecular methods, NGS sequencing methods, etc.
[0006] The limitations of these traditional methods for identifying Acinetobacter baumannii are:
[0007] 1. All of these identification methods require the cultivation of Acinetobacter baumannii strains, which takes a long time and is prone to contamination during the cultivation process.
[0008] 2. These identification methods can only identify a specific type of strain, and have serious lags in the diagnosis and treatment of diseases (after symptoms appear, the results cannot be known in time).
[0009] 3. Traditional bacterial molecular identification takes a long time (about 1-2 hours) to extract bacterial genomes, and the steps are complicated. Improper operation during the extraction process can easily cause environmental pollution.
[0010] 4. Conventional strain identification is costly and time-consuming, and is inconvenient and costly for clinical patients.
[0011] Therefore, there is an urgent need for a method for identifying Acinetobacter baumannii that is rapid, sensitive, highly specific, easy to operate and low-cost. Summary of the invention
[0012] In order to solve the technical problem that the prior art lacks a method for identifying Acinetobacter baumannii that is rapid, sensitive, highly specific and easy to operate, the present invention mainly innovates on the principle of combining RPA isothermal amplification technology with test strip detection, and provides a primer pair, a gene probe and a kit and their application in identifying Acinetobacter baumannii.
[0013] The present invention designs a pair of conservative primers and probes based on the conservative region of Acinetobacter baumannii, and uses the RPA amplification method to establish a visual nucleic acid test strip detection technology for detecting Acinetobacter baumannii. The test first extracts the genome of the sample, then performs RPA amplification on the extracted sample, and finally drips the amplified sample onto the test strip, and the development of the test strip indicates whether the strain exists in the sample.
[0014] In a first aspect, the present invention provides a primer pair for specific amplification of Acinetobacter baumannii, the primer pair comprising a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in any one of SEQ ID NOs: 1-4, and the nucleotide sequence of the reverse primer is shown in any one of SEQ ID NOs: 5-8;
[0015] Preferably, the nucleotide sequence of the forward primer is shown in SEQ ID NO:1, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:6; or, the nucleotide sequence of the forward primer is shown in SEQ ID NO:1, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:7; or, the nucleotide sequence of the forward primer is shown in SEQ ID NO:3, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:7; or, the nucleotide sequence of the forward primer is shown in SEQ ID NO:4, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO:8;
[0016] And / or, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
[0017] The second aspect of the present invention provides a gene probe coupled with digoxigenin labeling, wherein the nucleotide sequence of the gene probe is shown in SEQ ID NO:11 or SEQ ID NO:12.
[0018] The third aspect of the present invention provides a primer-probe combination, wherein the primer-probe combination comprises the primer pair as described in the first aspect and / or the gene probe as described in the second aspect of the present invention;
[0019] Preferably, the primer-probe combination comprises a nucleotide sequence of a forward primer such as SEQ ID NO: 4 shows and reverse The nucleotide sequence of the primer is as shown in SEQ ID NO:8, and the nucleotide sequence of the primer is as shown in SEQ ID NO:8. A gene probe with a sequence as shown in SEQ ID NO:12; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:1 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:6, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:11; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:1 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:7, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:11; or, the primer-probe combination comprises a primer pair with a nucleotide sequence of a forward primer as shown in SEQ ID NO:3 and a nucleotide sequence of a reverse primer as shown in SEQ ID NO:7, and a gene probe with a nucleotide sequence as shown in SEQ ID NO:11;
[0020] More preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
[0021] A fourth aspect of the present invention provides a test strip, the test strip comprising a sample pad, a conjugation pad, a nitrocellulose membrane and an absorption pad, the conjugation pad comprising microsphere solution 1 and microsphere solution 2; the nitrocellulose membrane comprising a detection line T line and a quality control line C line;
[0022] The microsphere solution 1 contains microspheres labeled with streptavidin; the microsphere solution 2 contains microspheres labeled with mouse anti-human antibody; the detection line T contains digoxigenin antibody, and the quality control line C contains goat anti-mouse antibody;
[0023] In some preferred embodiments, the test strip meets one or more of the following conditions:
[0024] (1) The particle size of the microspheres is 100-300 nm, for example, 200 nm;
[0025] (2) the molar concentration ratio of streptavidin in the microsphere solution 1 to the digoxigenin antibody in the detection line T is 1:1; and,
[0026] (3) The binding pad is a colloidal gold binding pad, and the amount of gold sprayed onto the microspheres is, for example, 6 μl / cm.
[0027] In the present invention, the detection line T has digoxin antibody, and the quality control line C has goat anti-mouse antibody; there are two kinds of microspheres on the colloidal gold binding pad: one is a microsphere labeled with streptavidin (SA), and the other is a microsphere labeled with mouse anti-human antibody. When the test strip is used for sample detection, since the amplified positive sample is labeled with biotin and digoxin, the sample is added to the glass fiber sample pad and flows to the colloidal gold binding pad. At this time, biotin will bind to the microspheres labeled with SA to generate a "microsphere-SA-biotin-positive fragment-digoxin" complex, which will reach the detection line T line along the flow direction. At this time, the complex will bind to the digoxin antibody and intercept the complex at the detection line T line, so the positive fragment will be colored on the detection line T line; if there is no positive fragment in the sample, the complex will not be formed, so the band will not appear on the detection line T line; another microsphere on the colloidal gold binding pad is a mouse anti-human microsphere, which will flow forward with the addition of the sample and will not react with the digoxin antibody on the detection line T line, but will continue to flow forward to the quality control line C line, react with the goat anti-mouse antibody on the quality control line C line, and the microsphere will be intercepted and colored at the quality control line C line.
[0028] The fifth aspect of the present invention provides a use of the primer pair described in the first aspect of the present invention, the gene probe described in the second aspect of the present invention, the primer-probe combination described in the third aspect of the present invention and / or the test strip described in the fourth aspect of the present invention in the preparation of a kit for identifying Acinetobacter baumannii.
[0029] The sixth aspect of the present invention provides a kit for identifying Acinetobacter baumannii, wherein the kit is selected from one or more of the primer pair provided in the first aspect of the present invention, the gene probe provided in the second aspect of the present invention, the primer-probe combination provided in the third aspect of the present invention, and the test strip provided in the fourth aspect of the present invention;
[0030] In some preferred embodiments, the kit further comprises a nucleic acid extraction reagent and / or a sample release buffer; the nucleic acid extraction reagent is an alkaline reagent, and the sample release buffer comprises a phosphate buffered saline solution;
[0031] In some more preferred embodiments, the nucleic acid extraction reagent is KOH and / or the sample release buffer is PBST+0.05% Triton.
[0032] In some embodiments, the method for preparing the test strip comprises the following steps:
[0033] i) preparing microsphere solution 1 and microsphere solution 2;
[0034] ii) The test strip is sprayed with gold film.
[0035] In some embodiments, the preparation of the microsphere solution 1 and the microsphere solution 2 in i) specifically comprises the following steps:
[0036] a) Mix the microspheres with a particle size of 100-300 nm and the activation buffer in two tubes at a volume ratio of 1:7;
[0037] b) Add streptavidin to the first tube at a final concentration of 0.1 to 0.15 mg / mL; add mouse anti-human antibody to the second tube at a final concentration of 0.1 to 0.15 mg / mL;
[0038] c) Add 1-ethyl-(3-dimethoxy-1-nitropropene) to the two solutions in b) at a final concentration of 1-10 mg / mL. methylaminopropyl)carbodiimide, placed in a constant temperature shaker at a speed of 80-120 rpm and a temperature of 22-26° C. for reaction for 50-70 minutes;
[0039] d) After the reaction is completed, ultrasonicate, add blocking agents respectively, ultrasonicate, and continue to place in a constant temperature shaker at a speed of 80 to 120 rpm and a temperature of 22 to 26° C. for blocking, and the blocking time is 80 to 100 minutes;
[0040] e) After blocking, centrifuge for 20 minutes, discard the supernatant, resuspend the precipitates in the first tube and the second tube with PBS to obtain microsphere solution 1 and microsphere solution 2, and store them in a refrigerator at 2-8°C for later use.
[0041] In some preferred embodiments, the particle size of the microspheres is 200 nm; the activation buffer is a HEPES solution; the final concentration of streptavidin is 0.125 mg / mL; the final concentration of the mouse anti-human antibody is 0.125 mg / mL; the final concentration of 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 1 mg / mL; the blocking agent is a CE510 solution; the rotation speed is 100 rpm, the temperature is 24°C, the reaction time is 60 mins; and the blocking time is 90 mins.
[0042] In some more preferred embodiments, the HEPES solution has a concentration of 5.6 g / L and a pH of 7.45.
[0043] In some embodiments, the test strip gold-sprayed film in ii) specifically comprises the following steps:
[0044] (1) diluting the microsphere solution 1 and the microsphere solution 2 prepared in step (i) by 15 to 25 times with a PBS solution;
[0045] (2) first spraying the diluted microsphere solution 1 of (1) onto the test strip at a concentration of 5 to 7 μl / cm, and drying; then spraying the diluted microsphere solution 2 of (1) onto the test strip at a concentration of 5 to 7 μl / cm, and drying;
[0046] (3) Using a film-spraying gold sprayer, digoxin antigen protein is sprayed on the nitrocellulose membrane as the detection line T line, and goat anti-mouse antibody is sprayed as the quality control line C line to obtain a test strip.
[0047] In some preferred embodiments, the dilution is 20-fold; and the concentration is 6 μl / cm.
[0048] The seventh aspect of the present invention provides a method for identifying Acinetobacter baumannii in a sample for non-diagnostic purposes, the method comprising using the primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention, the test strip as described in the fourth aspect of the present invention and / or the kit as described in the sixth aspect of the present invention;
[0049] In some preferred embodiments, the method comprises the following steps:
[0050] (I) performing RPA amplification on the DNA extracted from the sample to be tested using the primer pair described in the first aspect of the present invention, the gene probe described in the second aspect of the present invention, and / or the primer-probe combination described in the third aspect of the present invention to obtain an RPA amplification product; and,
[0051] (II) mixing the RPA amplification product and the sample release buffer in a volume ratio of 1:5, and adding the mixture to the test strip according to the fourth aspect of the present invention;
[0052] In some more preferred embodiments, the method further comprises:
[0053] (III) determining whether Acinetobacter baumannii is present in the sample to be tested based on the information on the test strip obtained after implementing step (II);
[0054] The judgment conditions for judging the positive or negative of the sample are: when the test strip has a detection line T line and a quality control line C line, it means that the result is positive and Acinetobacter baumannii is present in the sample to be tested; when the test strip has only a quality control line C line but no detection line T line, it means that the result is negative and Acinetobacter baumannii is not present in the sample to be tested; when the test strip has no quality control line C line, the result is invalid.
[0055] In some embodiments, the DNA sample is obtained by a nucleic acid extraction reagent (alkaline reagent, such as KOH or NaOH).
[0056] In some embodiments, the nucleic acid extraction reagent is 0.1 M KOH.
[0057] In the present invention, the application scenarios of "non-diagnostic purposes" include, for example, detecting Acinetobacter baumannii in the environment, detecting Acinetobacter baumannii on the surface of contact lenses, etc.
[0058] An eighth aspect of the present invention provides an identification system for Acinetobacter baumannii, the identification system comprising:
[0059] (1) an information collection module: used to collect information on the test strip obtained after using the method according to the sixth aspect of the present invention; and,
[0060] (2) Identification module: used to determine whether the sample to be tested contains Acinetobacter baumannii; the judgment criteria are:
[0061] a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b;
[0062] b. If there is a T line, it is judged as positive for Acinetobacter baumannii; if there is no T line, it is judged as negative for Acinetobacter baumannii;
[0063] (3) Data storage module: used to store user information, detection time, judgment results and other information, which includes user information, detection time and / or judgment results to facilitate the subsequent recording and tracking of pathogen infection information.
[0064] A ninth aspect of the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program implements the identification system as described in the eighth aspect of the present invention.
[0065] The tenth aspect of the present invention provides an electronic device comprising a memory, a processor and a computer program stored in the memory and executable on the processor, wherein the processor implements the identification system as described in the eighth aspect of the present invention when executing the computer program.
[0066] The eleventh aspect of the present invention provides a primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention, the test strip as described in the fourth aspect of the present invention, the kit as described in the sixth aspect of the present invention, the identification system as described in the eighth aspect of the present invention, the computer-readable storage medium as described in the ninth aspect of the present invention and / or the electronic device as described in the tenth aspect of the present invention for use in identifying whether a sample contains Acinetobacter baumannii.
[0067] In some embodiments, the application is for non-diagnostic purposes, such as detecting Acinetobacter baumannii in the environment, detecting Acinetobacter baumannii on the surface of contact lenses, etc.
[0068] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0069] The reagents and raw materials used in the present invention are commercially available.
[0070] The positive and progressive effects of the present invention are:
[0071] The present invention can perform RPA amplification identification on all types of Acinetobacter baumannii by designing specific RPA amplification primers and gene probes for the conserved sequences of Acinetobacter baumannii. Utilizing the specific amplification primers and gene probes of the present invention, the false positive phenomenon caused by the generation of primer dimers during the RPA amplification process can be effectively avoided, so that the identification result is more accurate. It has the advantages of being fast, sensitive, highly specific, easy to operate, and low in cost. The present invention proposes a method and system for identifying Acinetobacter baumannii, which can more conveniently, quickly and accurately identify the type of Acinetobacter baumannii, is conducive to the identification and research of Acinetobacter baumannii, and provides substantial reference suggestions for clinical diagnosis and treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 The figure is the gel electrophoresis diagram of nucleic acid extraction from different strains using different alkaline reagents; M is Marker; NC is negative control; the order of samples is: 1, Staphylococcus aureus; 2, Pseudomonas aeruginosa; 3, Acinetobacter baumannii; 4, Klebsiella pneumoniae; 5, Rhizopus oryzae; 6, Mucor circinelloides.
[0073] Figure 2 The effect of adding specific probes on the detection results.
[0074] Figure 3A-3B The results of the initial screening of primer pairs for the amplification of Acinetobacter baumannii were optimized; the sample order was: 1, 1 ng / μl; 2, 0.1 ng / μl; 3, 0.01 ng / μl; 4, NC; among them, Figure 3B for Figure 3A A partial enlarged view of the red circle.
[0075] Figure 4 The results of the test strip screening are as follows:
[0076] 1. AB-F1 / AB-R2 / AB-PR1-DIG;
[0077] 2. AB-F1 / AB-R3 / AB-PR1-DIG;
[0078] 3. AB-F3 / AB-R3 / AB-PR1-DIG;
[0079] 4. AB-F4 / AB-R4 / AB-PR2-DIG.
[0080] Figure 5 The figure is the gel electrophoresis diagram of the detection results of different markers; lanes 1-8 are: 1. PCR product labeled with digoxin; 2. PCR product labeled with digoxin combined with digoxin antibody-5; 3. PCR product labeled with digoxin combined with digoxin antibody-6; 4. PCR product labeled with digoxin combined with digoxin antibody-12; 5. PCR product labeled with digoxin combined with digoxin antibody-13; 6. PCR product labeled with digoxin combined with digoxin antibody-14; 7. RPA product labeled with FITC; 8. RPA product labeled with FITC combined with FITC antibody.
[0081] Figure 6 For the selection of biotin and digoxigenin labeling concentrations; lanes 1-8 are: 1. RPA product labeled with biotin and digoxigenin (labeled product); 2. Labeled product: SA=4:1; 3. Labeled product: SA=2:1; 4. Labeled product: SA=1:1; 5. Labeled product: SA=1:2; 6. Labeled product: DIG-13=4:1; 7. Labeled product: DIG-13=2:1; 8. Labeled product: DIG-13=1:1.
[0082] Figure 7 Optimization of release buffer for samples.
[0083] Figure 8 It is a strip-specific test for different strain samples.
[0084] Fig. 9 The results of the primer sensitivity test strip test. Lane 1: 2*10 7 CFU / ml; Lane 2: 2*10 6 CFU / ml; Lane 3: 2*10 5 CFU / ml; Lane 4: 2*10 4 CFU / ml; Lane 5: 2*10 3 CFU / ml; Lane 6: 1*10 3 CFU / ml; Lane 7: 2*10 2 CFU / ml; Lane 8: sterile water.
[0085] Fig.10 Schematic diagram of the identification system for microbial species.
[0086] Fig.11 A schematic diagram of the structure of an electronic device. DETAILED DESCRIPTION
[0087] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0088] Example 1 Optimization of sample nucleic acid extraction method
[0089] First, the present invention provides a method for rapidly extracting a genome DNA sample of Acinetobacter baumannii. The steps of extracting a sample of Acinetobacter baumannii with a sample release agent are as follows: taking 20 μl of the sample, adding 95 μl of 0.1M KOH, 0.5mM EDTA, and vortexing to mix; placing in a 90°C metal bath for incubation for 5 minutes; then standing at room temperature to restore the temperature to room temperature, a flocculent precipitate is precipitated, placing in a centrifuge at 10,000 rpm for 2 minutes, taking the supernatant and adding a sample preservation solution (Tris-HCl buffer, pH 8.0, 20 μl) to obtain an extracted genome solution.
[0090] The sample crude extraction method was tested on fungi, Gram-positive bacteria, and Gram-negative strains. For the selection of alkaline reagents, 0.1M sodium hydroxide (NaOH) and 0.1M potassium hydroxide (KOH) were selected as the test reagents, and the remaining steps were consistent with the sample release agent treatment method for Acinetobacter baumannii.
[0091] PCR amplification verification was performed on the extracted DNA of Acinetobacter baumannii samples. The specific amplification primers and probe sequences of Acinetobacter baumannii are shown in Table 3; 16sDNA-F / R (see Table 3) was selected for the primer pair for bacterial verification, and ITS1 / ITS4 primer pair (see Table 3) was selected for the primer pair for fungal verification. The PCR amplification system and amplification procedure are shown in Tables 1 and 2:
[0092] Table 1 PCR amplification system
[0093]
[0094] Table 2 PCR amplification program
[0095]
[0096] The amplification results were identified using 2% agarose gel. Figure 1 As shown. Figure 1 It can be seen that the selection of potassium hydroxide (KOH) as the alkaline hydrolysis reagent in the lysis reagent can play a significant role in the extraction, and the extracted sample can be normally subjected to subsequent amplification reactions.
[0097] Example 2 Addition of probes to the system
[0098] For the traditional RPA amplification combined with test strip detection method, only a pair of labeled forward and reverse primers need to be designed, but primer dimers will be generated, resulting in false positive test results. This method adds a labeled specific probe (SEQ ID NO: 12) to the RPA amplification system, which can make primer dimers undetectable in the test strip.
[0099] Specific results such as Figure 2 As shown: When the probe is added, the T line of NC in the amplification system does not appear, and if the probe is not added, the primer dimers that appear will bind to the T line and cause a false positive.
[0100] Example 3 Optimization and screening of primer pairs for RPA amplification of Acinetobacter baumannii
[0101] The present invention provides amplification primers specific for Acinetobacter baumannii, the sequences of which include: SEQ ID NO: 1-8, wherein the fragment size of the product obtained by sequence amplification by the primer pair is about 208 bp. SEQ ID NO: 9-12 are probe sequences, and the sequence information is shown in Table 3:
[0102] Table 3 Amplification primer pairs and probe sequences
[0103]
[0104] Note: 1. "F", "R" and "PR" in the primer names represent the upstream, downstream and probe sequences of the primers respectively.
[0105] 2. FAM-dT is a FAM labeling group, DIG-dT is a DIG labeling group, BHQ1-dT is a BHQ1 labeling group, THF is a tetrahydrofuran molecule, and C3-spacer is a blocking group at the 3' end. The 5' end of the reverse primer (AB-R1 to AB-R4) is labeled with Biotin.
[0106] 3. The two probes AB-PR1-FAM and AB-PR1-DIG have the same sequence but different labels. AB-PR1-FAM is used to label FAM fluorescent signal and BHQ1 quencher group in fluorescence screening; AB-PR1-DIG is used to label DIG antibody for screening and detection on test strips. The two probes AB-PR2-FAM and AB-PR2-DIG have the same sequence but different labels. AB-PR2-FAM is used to label FAM fluorescent signal and BHQ1 quencher group in fluorescence screening; AB-PR2-DIG is used to label DIG antibody for screening and detection on test strips.
[0107] 3.1 Fluorescence screening
[0108] (1) According to the arranged sample sequence, the corresponding samples are marked on the PCR reaction 96-well plate (i.e., reaction plate, whose naming rule is "experimental date-sample label-site information") or 200 μl reaction tube of the biotechnology. Use a pipette to transfer the bacterial liquid samples of Acinetobacter baumanniie (ATCC17978) from the sample tube in sequence. According to the optimized nucleic acid extraction method of Example 1, the nucleic acid sample of Acinetobacter baumanniie is extracted. The nucleic acid sample should be added to the bottom of the reaction well; if the sample is not added to the bottom of the reaction well during the sample addition process, it should be briefly centrifuged after the sample addition is completed, and the extracted Acinetobacter baumannii genomic DNA product is obtained after the reaction is completed. The samples used in the screening process are: 1 ng / μl, 0.1 ng / μl, 0.01 ng / μl, and sterile water (NC) extracted from Acinetobacter baumannii. These four samples are screened and tested.
[0109] (2) Use the primer and probe combinations in Table 1 respectively, ①AB-F1 / AB-R1 / AB-PR1-FAM, ②AB-F1 / AB-R2 / AB-PR1-FAM, ③AB-F1 / AB-R3 / AB-PR1-FAM, ④AB-F2 / AB-R1 / AB-PR1-FAM, ⑤AB-F2 / AB-R2 / AB-PR1-FAM, ⑥AB-F2 / AB-R3 / AB-PR1-FAM, ⑦AB-F3 / AB-R1 / AB-PR1-FAM, ⑧AB-F3 / AB-R2 / AB-PR1-FAM, ⑨AB-F3 / AB-R3 / AB-PR1-FAM, ⑩AB-F4 / AB-R4 / AB-PR2-FAM for amplification.
[0110] (3) Configure the RPA reaction system according to Table 4:
[0111] Table 4 RPA reaction system
[0112]
[0113]
[0114] After the system is configured as above, vortex mix, add 2.5 μl of the activator in the DNA constant temperature rapid amplification kit, vortex mix, and place in the ABI7300 real-time fluorescence quantitative PCR reaction instrument for constant temperature reaction at 39°C for 20 minutes.
[0115] (5) Fluorescence curve results are as follows Figure 3A and Figure 3B shown.
[0116] Different primer probe pair combinations were screened, among which: ②AB-F1 / AB-R2 / AB-PR1-FAM; ③AB-F1 / AB-R3 / AB-PR1-FAM; ⑨AB-F3 / AB-R3 / AB-PR1-FAM; ⑩AB-F4 / AB-R4 / AB-PR2-FAM had shorter signal values and reaction threshold time. Therefore, these four primer probe pairs were selected for further testing.
[0117] 3.2 Test strip screening
[0118] (1) According to the arranged sample sequence, the corresponding samples are marked on the PCR reaction 96-well plate (i.e., reaction plate, whose naming rule is "experiment date-sample label-site information") or 200μl reaction tube of the Biotech company. Use a pipette to transfer the bacterial liquid samples of Acinetobacter baumanniie (ATCC17978) from the sample tube in sequence. Extract the Acinetobacter baumanniie liquid sample according to the above optimized extraction method. The sample should be added to the bottom of the reaction well; if the sample is not added to the bottom of the reaction well during the addition process, it should be centrifuged briefly after the addition is completed. After the reaction is completed, the extracted Acinetobacter baumanniie genomic DNA product is obtained. The samples used in the screening process are: Acinetobacter baumanniie extracted samples 0.01ng / μl, 1pg / μl, 0.1pg / μl, and sterile water (NC). These four samples are screened and tested.
[0119] (2) Amplification was performed using primer-probe combinations: AB-F1 / AB-R2 / AB-PR1-DIG; AB-F1 / AB-R3 / AB-PR1-DIG; AB-F3 / AB-R3 / AB-PR1-DIG; AB-F4 / AB-R4 / AB-PR2-DIG.
[0120] (3) Prepare the RPA reaction system according to Table 5:
[0121] Table 5 RPA reaction system
[0122]
[0123]
[0124] After configuring the system as above, vortex mix, add 2.5 μl of the activator in the DNA constant temperature rapid amplification kit, vortex mix, and incubate in a 39°C constant temperature bath for 10 minutes.
[0125] (4) For test strip detection: Take 15 μl of the amplified product and add it to 75 μl of sample buffer. Vortex to mix well and then add it to the treated test strip. Wait for about 3 minutes to determine whether it is positive or negative.
[0126] result Figure 4 As shown. Figure 4 It can be seen that for the fourth pair of primer-probe combinations, samples with a detection sample concentration of 0.1pg / μl can also be detected, while the sensitivity of the remaining primer-probe combinations is not as good as the fourth pair of primer-probe combinations. Therefore, the primer-probe combination ⑩AB-F4 / AB-R4 / AB-PR2-DIG is more obvious for the identification result. For low-concentration samples, primer-probe combinations with poor amplification efficiency may not amplify the target band, while for primer-probe combinations with higher amplification efficiency, they can amplify the target band, thus proving that the primer-probe combination provided by the present invention can improve the sensitivity of detection.
[0127] Example 4 Preparation of digoxin antibody and FITC antibody
[0128] The following homemade antibodies are for cost considerations, and it is not necessary to use the homemade antibodies of the present invention. Those skilled in the art can prepare antibodies according to conventional methods, such as by the following subclone screening, hybridoma cells are inoculated into mice to collect ascites, and the method of purifying ascites is prepared and screened to obtain the target antibody with good specificity. Alternatively, conventional commercially available digoxin antibodies and FITC antibodies can also be selected. As long as the antibody used can produce a polymer binding with the RPA amplification product with the corresponding antigen marker, the technical effect of the present invention can be achieved.
[0129] The monoclonal antibody used in the example was developed on Balb / c mice using digoxin-BSA complex (Shanghai Maiye Biotechnology Co., Ltd., catalog number: Digoxin-BSA 230510#) as an immunogen. The first intradermal immunization was performed using digoxin-BSA complex (100 μg, as an immunogen) in 100 μl emulsion prepared with Freund's complete adjuvant, and 100 μg of immunogen in 100 μl emulsion prepared with Freund's incomplete adjuvant was used for enhanced immunization 25 days later. 50 μg of immunogen was used for intradermal immunization twice, with an interval of 4 weeks, and then 50 μg of immunogen was used in 100 μl Hanks balanced salt solution (China Bishi Biotechnology Co., Ltd.) for pre-fusion promotion intravenously and intraperitoneally (the IgG1 antibody strain in the example was obtained by fusion at the first immunization). Hybridoma cell lines secreting digoxin-specific antibodies were generated using standard fusion technology. After extensive screening, several anti-digoxin antibody clones with good specificity were selected for the development of rapid detection and screening of Acinetobacter baumannii.
[0130] Antibody subtype testing: A commercially available antibody subtype identification kit (ELISA) was used to identify the subtypes of several digoxin-specific antibodies that were screened. The identification results are shown in Table 6:
[0131] Table 6 Anti-digoxin antibody subtype identification results
[0132]
[0133] The monoclonal antibody used in the example was developed on Balb / c mice using FITC-OVA complex (Shanghai Maiye Biotechnology Co., Ltd., catalog number: FITC-OVA 240206#) as an immunogen. The first intradermal immunization was performed with FITC-OVA complex (100 μg, as an immunogen) in 100 μl emulsion prepared with Freund's complete adjuvant, and 25 days later, 100 μg of immunogen in 100 μl emulsion prepared with Freund's incomplete adjuvant was used for enhanced immunization. Then, 50 μg of immunogen was used for intradermal immunization twice, with an interval of 4 weeks, and then 50 μg of immunogen was used for intravenous and intraperitoneal prefusion promotion in 100 μl Hanks balanced salt solution (China Bishi Biotechnology Co., Ltd.) (the IgG1 antibody strain in the example was obtained by fusion at the first immunization). Hybridoma cell lines secreting digoxin-specific antibodies were produced using standard fusion technology. After extensive screening, anti-FITC antibody clones with good specificity were selected for the development of rapid detection of Acinetobacter baumannii.
[0134] Antibody subtype testing: The commercially available antibody subtype identification kit (ELISA) was used to identify the subtype FITC-6 of the screened anti-FITC specific antibodies. The identification results are shown in Table 7:
[0135] Table 7 Identification results of anti-FITC antibody subtype FITC-6
[0136]
[0137] Example 5 Screening of markers and antibodies thereof
[0138] In this embodiment, markers and antibodies were tested using Pseudomonas aeruginosa as an example. The primers (PA-lasB-F3 / R3) of Pseudomonas aeruginosa are shown in Table 8. Two markers, digoxin (DIG) and fluorescein isothiocyanate (FITC), were selected to be labeled at the 5' end of the reverse primer (PA-lasB-R3), and performance comparison and identification were performed. The amplification method is consistent with the PCR amplification system detection method of Table 1 for detecting Acinetobacter baumannii described in Example 1. The amplified PCR products labeled with digoxin were incubated at room temperature for 3 minutes with digoxin antibodies (digoxin antibodies-5, digoxin antibodies-6, digoxin antibodies 12, digoxin antibodies-13 or digoxin antibodies-14); the amplified PCR products labeled with FITC were incubated at room temperature for 3 minutes with FITC antibodies. (Wherein digoxin antibodies and FITC antibodies are prepared by Example 4). Finally, the incubated reaction was subjected to agarose gel electrophoresis to identify the binding efficiency of the antibody and the labeled PCR product. Figure 5shown.
[0139] Depend on Figure 5 It can be seen that the PCR products in lanes 4 and 5 can produce multimers with digoxigenin antibody, and the multimer band produced in lane 5 is brighter, which indicates that digoxigenin antibody-13 can produce multimers with PCR products and its efficiency is higher than that of other lanes. Therefore, digoxigenin was selected as the primer marker and digoxigenin antibody-13 as the subsequent labeling antibody.
[0140] Table 8 Pseudomonas aeruginosa PCR amplification primer pair sequence
[0141] Primer name Sequence 5'-3' SEQ ID NO. PA-lasB-F3 GCAAGACCGAGAATGACAAAGTGGAACTGGTGATC 17 PA-lasB-R3 ATCGAGCACTTCGCCGGTCTTGGCGTCGATG 18
[0142] Example 6 Selection of biotin and digoxigenin labeling concentrations
[0143] In this example, Pseudomonas aeruginosa was used as an example to screen the concentrations of biotin and digoxigenin labels (the primers and probe sequences used for amplification are shown in Table 8, and the 5' end of the reverse primer PA-lasB-R3 is labeled with Biotin). For the markers biotin and digoxigenin on the amplified product, they need to be combined with streptavidin (SA) and digoxigenin antibody on the test strip later, and now it is necessary to screen the concentration ratio of biotin and digoxigenin antibody. The remaining steps are consistent with the amplification detection method for detecting Acinetobacter baumannii described in Example 1. The PCR products labeled with biotin and digoxigenin after PCR amplification were gradient screened with streptavidin (SA) and digoxigenin antibody (DIG-13) according to the molar concentration ratio, and incubated at room temperature for 3 minutes, and then agarose gel electrophoresis was performed to identify the binding efficiency. The electrophoresis results are shown in FIG. Figure 6 shown.
[0144] Depend on Figure 6 It can be seen that for lanes 4 and 5, the PCR product can produce significant multimer binding with SA; for lane 8, the PCR product can produce significant multimer binding with DIG-13, indicating that the subsequent polymerization amplification of the signal value can be performed through the multimer. Therefore, the concentration of PCR product: SA: DIG-13 = 1:1:1 was selected for the test strip detection.
[0145] Example 7 Sample Release Buffer Optimization
[0146] Direct testing of the sample with a test strip after RPA amplification will result in the test strip not being able to be developed (because the sample after amplification is viscous, which makes it impossible to perform capillary action and cannot be developed on the test strip), so the sample release buffer is optimized. Select 2.0*10 5Nucleic acid extraction and RPA amplification were performed on Acinetobacter baumannii samples with a sample concentration of CFU / ml (the primer probe combination used was SEQ ID NO: 4, 8 and 12), and water, PBS, and PBST+0.05% Triton solution were selected as sample release buffers for comparative detection tests. The results are shown in Figure 7 shown.
[0147] From the above comparative tests of different sample release buffers, it can be seen that PBST+0.05% Triton solution can fully release the amplified sample and obtain a more sensitive detection.
[0148] Example 8 Preparation of Test Strips
[0149] 1. Preparation of labeled microspheres
[0150] Take two tubes of 200 μl of 200 nm blue microspheres (Jiaxing Maijin Biotechnology Co., Ltd.), add 1400 μl of activation buffer (HEPES solution 5.6 g / L pH 7.45), blow and mix; add 0.2mg streptavidin (SA) solution to the first tube of microsphere 1, and add mouse anti-human antibody (0.2mg, Merck, catalog number: I6760) to the second tube of microsphere 2; add EDC (1-ethyl-(3-dimethylaminopropyl) carbodiimide) with a final concentration of 1mg / mL9 to the tube wall, quickly shake up and down to mix, and place in a constant temperature reaction for 60mins (24℃, 100rpm); after the reaction, ultrasonicate each tube 5 times, add 100μl of blocking agent (CE510 solution), ultrasonicate again 5 times, and continue to place in a constant temperature shaker for blocking for 90mins (100rpm, 24℃); after the blocking is completed, centrifuge for 20min (13000rpm, 4℃), discard the supernatant, and resuspend the precipitate with 2ml PBS storage buffer; store in a 2-8℃ refrigerator for later use.
[0151] 2. Gold coating on test strips
[0152] The two tubes of labeled microsphere solutions prepared above were diluted 20 times with PBS solution, and then the microsphere 1 was sprayed with gold at a concentration of 5 μl / cm, and then dried in a dryer; then the microsphere 2 was sprayed with gold and dried. Digoxin antibody (DIG-13) was sprayed on the nitrocellulose membrane using a film spraying instrument as the test line (T line) and goat anti-mouse antibody (Sigma, catalog number: A9309-1mL) as the quality control line (C line).
[0153] Take 15μl of the amplified product and add it to 75μl of sample buffer, vortex and mix, then add it to the treated test strip, and wait for about 3 minutes to determine whether it is positive or negative. When both the test line (T line) and the quality control line (C line) of the test strip have bands, it means that the result is positive and Acinetobacter baumannii exists; if only the quality control line has a band and there is no band at the test line, it means that the result is negative and Acinetobacter baumannii does not exist; if no band appears on the quality control line, the result is invalid.
[0154] Example 9 Sample-specific test strip detection
[0155] Specific detection was performed for different strain samples. The remaining steps were consistent with the RPA detection method for detecting Acinetobacter baumannii described in Example 3. RPA amplification verification was performed on the extracted DNA of different samples (the primer probe pair used was AB-F4 / AB-R4 / AB-PR2-DIG, SEQ ID NO: 4, 8 and 12). The results are shown in Figure 8 As shown, the samples are: Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Rhizopus oryzae, and NC.
[0156] The above different strain types are common strains. Figure 8 It can be seen that the primer-probe combination of the present invention can specifically detect Acinetobacter baumannii samples and is exclusive and specific to Acinetobacter baumannii samples.
[0157] Example 10 Sample sensitivity test strip detection
[0158] For the samples of Acinetobacter baumannii, gradient dilution was performed with sterile saline, and different concentrations (1:2*10 7 CFU / ml, 2:2*10 6 CFU / ml, 3:2*10 5 CFU / ml, 4:2*10 4 CFU / ml, 5:2*10 3 CFU / ml, 6:1*10 3 CFU / ml, 7:2*10 2 CFU / ml) samples were tested for sensitivity. The remaining steps were consistent with the RPA detection method for Acinetobacter baumannii described in Example 3. The extracted DNA of Acinetobacter baumannii samples was verified by RPA amplification (the primer probe combination used was SEQ ID NO: 4, 8 and 12). The results are shown in Fig. 9 , where the sample order is 1:2*10 7 CFU / ml, 2:2*10 6 CFU / ml, 3:2*10 5 CFU / ml, 4:2*104 CFU / ml, 5:2*10 3 CFU / ml, 6:1*10 3 CFU / ml, 7:2*10 2 CFU / ml, 8: sterile water.
[0159] Depend on Fig. 9 It can be seen that the primer pair provided by the present invention has a sample concentration of 1*10 3 CFU / ml, it can still be significantly detected. This proves that the primer-probe combination of the present invention has a high sensitivity. And from the trend of the band depth, it can be seen that the lower the sample concentration, the lighter the positive band, so the concentration of the strain in the sample can be seen from the depth of the positive band.
[0160] Example 11 Microbial Species Identification System
[0161] System 61 for identification of microbial species: information collection module 51, identification module 52 and data storage module 53 (see Fig.10 ).
[0162] The information collection module 51 is used to collect the test strip results and identify the uploaded result pictures;
[0163] The identification module 52 is used to determine whether the sample to be identified is Acinetobacter baumannii, and automatically upload and save the data. The judgment criteria for the identification are:
[0164] a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b;
[0165] b. If there is a T line, the result is considered positive for Acinetobacter baumannii; if there is no T line, the result is considered negative for Acinetobacter baumannii;
[0166] The data storage module 53 is used to store information, including user information, detection time and / or judgment results, to facilitate the subsequent recording and tracking of pathogen infection information.
[0167] Embodiment 12 Electronic device
[0168] This embodiment provides an electronic device, which can be expressed in the form of a computing device (for example, a server device), including a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the microbial species identification system of Embodiment 11 of the present invention can be implemented when the processor executes the computer program.
[0169] Fig.11 The hardware structure diagram of this embodiment is shown, and the electronic device 9 specifically includes:
[0170] At least one processor 91, at least one memory 92, and a bus 93 for connecting different system components (including the processor 91 and the memory 92), wherein:
[0171] The bus 93 includes a data bus, an address bus, and a control bus.
[0172] The memory 92 includes a volatile memory, such as a random access memory (RAM) 921 and / or a cache memory 922 , and may further include a read-only memory (ROM) 923 .
[0173] The memory 92 also includes a program tool 925 having a set (at least one) of program modules 924, such program modules 924 including but not limited to: an operating system, one or more application programs, other program modules and program data, each of which or some combination may include the implementation of a network environment.
[0174] The processor 91 executes various functional applications and data processing by running the computer programs stored in the memory 92, such as processing the sequence information in the sample and the sequence information in the database.
[0175] The electronic device 9 can further communicate with one or more external devices 94 (e.g., keyboards, pointing devices, etc.). Such communication can be performed through an input / output (I / O) interface 95. In addition, the electronic device 9 can also communicate with one or more networks (e.g., local area networks (LANs), wide area networks (WANs), and / or public networks, such as the Internet) through a network adapter 96. The network adapter 96 communicates with other modules of the electronic device 9 through a bus 93. It should be understood that, although not shown in the figure, other hardware and / or software modules can be used in conjunction with the electronic device 9, including but not limited to: microcode, device drivers, redundant processors, external disk drive arrays, RAID (disk array) systems, tape drives, and data backup storage systems, etc.
[0176] It should be noted that although several units / modules or sub-units / modules of the electronic device are mentioned in the above detailed description, this division is merely exemplary and not mandatory. In fact, according to the embodiments of the present application, the features and functions of two or more units / modules described above can be embodied in one unit / module. Conversely, the features and functions of one unit / module described above can be further divided into multiple units / modules to be embodied.
[0177] Embodiment 13 Computer readable storage medium
[0178] An embodiment of the present invention provides a computer-readable storage medium having a computer program stored thereon, and when the program is executed by a processor, the steps of the microbial species identification system of embodiment 11 of the present invention are implemented.
[0179] The readable storage medium may include but is not limited to: a portable disk, a hard disk, a random access memory, a read-only memory, an erasable programmable read-only memory, an optical storage device, a magnetic storage device or any suitable combination of the above.
[0180] In a possible implementation manner, the present invention may also be implemented in the form of a program product, which includes program codes. When the program product is run on a terminal device, the program codes are used to enable the terminal device to execute the steps of implementing the above-mentioned identification method.
[0181] The program code for executing the present invention may be written in any combination of one or more programming languages, and may be executed entirely on a user device, partially on a user device, as an independent software package, partially on a user device and partially on a remote device, or entirely on a remote device.
Claims
1. A primer pair for specific amplification of Acinetobacter baumannii, the primer pair comprising a forward primer and a reverse primer, characterized in that: The nucleotide sequence of the forward primer is shown in any one of SEQ ID NOs: 1-4, and the nucleotide sequence of the reverse primer is shown in any one of SEQ ID NOs: 5-8; Preferably, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:1, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:6; or, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:1, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:7; or, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:3, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:7; or, the nucleotide sequence of the forward primer is as shown in SEQ ID NO:4, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO:8; and / or, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
2. A gene probe coupled with digoxigenin labeling, characterized in that: The nucleotide sequence of the gene probe is shown in SEQ ID NO:11 or SEQ ID NO:
12.
3. A primer-probe combination, characterized in that: The primer-probe combination comprises the primer pair according to claim 1 and / or the gene probe according to claim 2; Preferably, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:4 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:8, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:12; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:6, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:11; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:7, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:11; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:3 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:7, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:11; More preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
4. A test strip comprising a sample pad, a conjugate pad, a nitrocellulose membrane and an absorption pad, characterized in that: The conjugate pad comprises microsphere solution 1 and microsphere solution 2; the nitrocellulose membrane comprises a detection line T line and a quality control line C line; The microsphere solution 1 contains microspheres labeled with streptavidin; the microsphere solution 2 contains microspheres labeled with mouse anti-human antibody; the detection line T contains digoxigenin antibody, and the quality control line C contains goat anti-mouse antibody; Preferably, the test strip meets one or more of the following conditions: (1) The particle size of the microspheres is 100-300 nm, for example, 200 nm; (2) the molar concentration ratio of streptavidin in the microsphere solution 1 to the digoxigenin antibody in the detection line T is 1:1; and, (3) The binding pad is a colloidal gold binding pad, and the amount of gold sprayed onto the microspheres is, for example, 6 μl / cm.
5. Use of the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3 and / or the test strip as claimed in claim 4 in the preparation of a kit for identifying Acinetobacter baumannii.
6. A kit for identifying Acinetobacter baumannii, characterized in that: The kit comprises one or more selected from the group consisting of the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3, and the test strip as claimed in claim 4; Preferably, the kit further comprises a nucleic acid extraction reagent and / or a sample release buffer; the nucleic acid extraction reagent is an alkaline reagent, and the sample release buffer comprises a phosphate buffered saline solution; More preferably, the nucleic acid extraction reagent is KOH and / or the sample release buffer is PBST+0.05% Triton.
7. A method for identifying Acinetobacter baumannii in a sample for non-diagnostic purposes, characterized in that: The method comprises using the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3, the test strip as claimed in claim 4 and / or the kit as claimed in claim 6; Preferably, the method comprises the following steps: (I) performing RPA amplification on the DNA extracted from the sample to be tested using the primer pair according to claim 1, the gene probe according to claim 2, and / or the primer-probe combination according to claim 3 to obtain an RPA amplification product; and, (II) mixing the RPA amplification product and the sample release buffer in a volume ratio of 1:5, and adding the mixture to the test strip as claimed in claim 4; More preferably, the method further comprises: (III) determining whether Acinetobacter baumannii is present in the sample to be tested based on the information on the test strip obtained after implementing step (II); The judgment conditions are: when the test strip has a detection line T line and a quality control line C line, it means that the result is positive and Acinetobacter baumannii is present in the sample to be tested; when the test strip has only a quality control line C line but no detection line T line, it means that the result is negative and Acinetobacter baumannii is not present in the sample to be tested; when the test strip has no quality control line C line, the result is invalid.
8. An identification system for Acinetobacter baumannii, characterized in that: The identification system comprises: (1) an information collection module: used to collect information on the test strip obtained by using the method according to claim 7; and, (2) Identification module: used to determine whether the sample to be tested contains Acinetobacter baumannii; the judgment criteria are: a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b; b. If there is a T line, it is judged as positive for Acinetobacter baumannii; if there is no T line, it is judged as negative for Acinetobacter baumannii; (3) Data storage module: used to store user information, detection time, judgment results and other information.
9. A computer-readable storage medium having a computer program stored thereon, characterized in that: The computer program implements the authentication system according to claim 8.
10. An electronic device comprising a memory, a processor, and a computer program stored in the memory and executable on the processor, characterized in that: When the processor executes the computer program, the authentication system according to claim 8 is implemented.
11. Use of the primer pair according to claim 1, the gene probe according to claim 2, the primer-probe combination according to claim 3, the test strip according to claim 4, the kit according to claim 6, the identification system according to claim 8, the computer-readable storage medium according to claim 9 and / or the electronic device according to claim 10 in identifying whether a sample contains Acinetobacter baumannii; Preferably, the use is for non-diagnostic purposes.
